Related Experiment Video
Updated: May 11, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study
Giuseppe Matullo1, Simonetta Guarrera, Marta Betti
1Human Genetics Foundation, HuGeF, Turin, Italy. giuseppe.matullo@unito.it
Abstract:
Asbestos exposure is the main risk factor for malignant pleural mesothelioma (MPM), a rare aggressive tumor. Nevertheless, only 5-17% of those exposed to asbestos develop MPM, suggesting the involvement of other environmental and genetic risk factors. To identify the genetic risk factors that may contribute to the development of MPM, we conducted a genome-wide association study (GWAS; 370,000 genotyped SNPs, 5 million imputed SNPs) in Italy, among 407 MPM cases and 389 controls with a complete history of asbestos exposure. A replication study was also undertaken and included 428 MPM cases and 1269 controls from Australia. Although no single marker reached the genome-wide significance threshold, several associations were supported by haplotype-, chromosomal region-, gene- and gene-ontology process-based analyses. Most of these SNPs were located in regions reported to harbor aberrant alterations in mesothelioma (SLC7A14, THRB, CEBP350, ADAMTS2, ETV1, PVT1 and MMP14 genes), causing at most a 2-3-fold increase in MPM risk. The Australian replication study showed significant associations in five of these chromosomal regions (3q26.2, 4q32.1, 7p22.2, 14q11.2, 15q14). Multivariate analysis suggested an independent contribution of 10 genetic variants, with an Area Under the ROC Curve (AUC) of 0.76 when only exposure and covariates were included in the model, and of 0.86 when the genetic component was also included, with a substantial increase of asbestos exposure risk estimation (odds ratio, OR: 45.28, 95% confidence interval, CI: 21.52-95.28). These results showed that genetic risk factors may play an additional role in the development of MPM, and that these should be taken into account to better estimate individual MPM risk in individuals who have been exposed to asbestos.
Insights
Genetic factors contribute to malignant pleural mesothelioma (MPM) risk beyond asbestos exposure. Identifying these genetic variants can improve risk prediction for asbestos-exposed individuals, enhancing understanding of this aggressive cancer.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- Asbestos exposure is the primary risk factor for malignant pleural mesothelioma (MPM).
- Only a subset of asbestos-exposed individuals develop MPM, indicating other contributing factors.
- Genetic predisposition is suspected to play a role in MPM development.
Purpose of the Study:
- To identify genetic risk factors associated with malignant pleural mesothelioma (MPM).
- To assess the combined effect of genetic variants and asbestos exposure on MPM risk.
Main Methods:
- Genome-wide association study (GWAS) in Italian MPM cases and controls with asbestos exposure history.
- Replication study in Australian MPM cases and controls.
- Analysis of single nucleotide polymorphisms (SNPs), haplotypes, and chromosomal regions.
Main Results:
- No single SNP reached genome-wide significance, but several regions and genes showed associations.
- Replication study confirmed associations in five chromosomal regions.
- Ten genetic variants independently contributed to MPM risk, significantly improving risk prediction models (AUC increased from 0.76 to 0.86).
Conclusions:
- Genetic factors play an additional role in the development of malignant pleural mesothelioma (MPM).
- These genetic risk factors, when combined with asbestos exposure, substantially increase MPM risk.
- Incorporating genetic information can enhance individual MPM risk assessment for asbestos-exposed populations.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Cancer Prevention
Some...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pleural Disorders: Types and Brief Description
